A more recent randomized controlled study called REFLEX trial (Randomized Evaluation of Long-Term Efficacy of Rituximab in RA) demonstrated that in patients who had inadequate response to one or more anti-TNFα agents, 2 infusions of 1000 mg of rituximab in addition to background MTX led to significantly higher response rates than MTX alone (EULAR moderate-to-good response 65% vs 22%) [14]. The gene discussed is TNF; the disease is rheumatoid arthritis.